Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.

Tomsitz D, Ruf T, Heppt M, Staeger R, Ramelyte E, Dummer R, Garzarolli M, Meier F, Meier E, Richly H, Gromke T, Siveke JT, Franklin C, Klespe KC, Mauch C, Kilian T, Seegräber M, Schilling B, French LE, Berking C, Heinzerling L (2023)

Publication Type: Journal article

Publication year: 2023

Journal

Cancers MDPI

Book Volume: 15

Journal Issue: 13

DOI: 10.3390/cancers15133430

Abstract

BACKGROUND: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting. PATIENTS AND METHODS: This retrospective, multicenter study analyzed the outcomes and safety of tebentafusp therapy in 78 patients with mUM. RESULTS: Patients treated with tebentafusp had a median PFS of 3 months (95% CI 2.7 to 3.3) and a median OS of 22 months (95% CI 10.6 to 33.4). In contrast to a published Phase 3 study, our cohort had a higher rate of patients with elevated LDH (65.4% vs. 35.7%) and included patients with prior systemic and local ablative therapies. In patients treated with tebentafusp following ICI, there was a trend for a longer median OS (28 months, 95% CI 26.9 to 29.1) compared to the inverse treatment sequence (24 months, 95% CI 13.0 to 35.0, p = 0.257). The most common treatment-related adverse events were cytokine release syndrome in 71.2% and skin toxicity in 53.8% of patients. Tumor lysis syndrome occurred in one patient. CONCLUSIONS: Data from this real-life cohort showed a median PFS/OS similar to published Phase 3 trial data. Treatment with ICI followed by tebentafusp may result in longer PFS/OS compared to the inverse treatment sequence.

Authors with CRIS profile

Markus Heppt Department of Dermatology Carola Berking Lehrstuhl für Haut- und Geschlechtskrankheiten

Involved external institutions

Klinikum der Universität München DE Germany (DE) Universitätsspital Zürich (USZ) CH Switzerland (CH) Universitätsklinikum Carl Gustav Carus Dresden DE Germany (DE) Universitätsklinikum Essen DE Germany (DE) Universitätsklinikum Würzburg DE Germany (DE)

How to cite

APA:

Tomsitz, D., Ruf, T., Heppt, M., Staeger, R., Ramelyte, E., Dummer, R.,... Heinzerling, L. (2023). Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study. Cancers, 15(13). https://doi.org/10.3390/cancers15133430

MLA:

Tomsitz, Dirk, et al. "Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study." Cancers 15.13 (2023).

BibTeX: Download